Teva Pharmaceutical Industries (TEVA) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $2.12.
- Teva Pharmaceutical Industries' Debt to Equity fell 3575.41% to $2.12 in Q4 2025 from the same period last year, while for Dec 2025 it was $2.12, marking a year-over-year decrease of 3575.41%. This contributed to the annual value of $2.12 for FY2025, which is 3575.41% down from last year.
- Per Teva Pharmaceutical Industries' latest filing, its Debt to Equity stood at $2.12 for Q4 2025, which was down 3575.41% from $2.31 recorded in Q3 2025.
- Teva Pharmaceutical Industries' 5-year Debt to Equity high stood at $3.31 for Q4 2024, and its period low was $2.05 during Q4 2021.
- For the 5-year period, Teva Pharmaceutical Industries' Debt to Equity averaged around $2.47, with its median value being $2.44 (2023).
- In the last 5 years, Teva Pharmaceutical Industries' Debt to Equity soared by 3542.88% in 2024 and then tumbled by 3575.41% in 2025.
- Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Debt to Equity stood at $2.05 in 2021, then rose by 20.38% to $2.47 in 2022, then fell by 1.07% to $2.44 in 2023, then surged by 35.43% to $3.31 in 2024, then plummeted by 35.75% to $2.12 in 2025.
- Its Debt to Equity stands at $2.12 for Q4 2025, versus $2.31 for Q3 2025 and $2.52 for Q2 2025.